ma macular degeneration? >> it sold 800 million, some of the reports i have read, reports in 2013, 1.5 billion. quickly took market share, due to many frequent, less frequent injection cycles, our product is in phase two, one has to be cautious. if it pans out, what we have seen in limited studies, our drug maybe lasts three to four months, what an advantage it would be for the patients to go, from say, ten injections per year, with lucentis to, say, seven or six for ilea, to potentially, three, four, if our technology, we have on license from switzerland all works out. >> that is injections into the the eye.